Continuing story · 1 report
FDA panel review of seven unapproved peptides
Gone quiet since
Where it stands
The FDA Pharmacy Compounding Advisory Committee began its two-day review of seven unapproved peptides on July 23. FDA career scientists recommended against compounding all seven, citing a lack of human clinical data for three and inadequate data for the others; the committee’s recommendations have not yet been reported.
Story trackerDay 1
1 report11 outlets11 sources1 video
The story so far
Update 1
Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record
A two-day meeting in Washington ended with a narrow recommendation to loosen compounding rules for unapproved compounds championed by influencers and RFK Jr. — over the objections of the agency's own staff.
Still open after this report
- Whether the FDA will adopt the committee's recommendation in full or in part.
- Which specific peptides failed to win a majority, given the gap between seven on the agenda and six (or four) endorsed.
History
Opened1 report
Who's involved
People
Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 report
Robert F. Kennedy Jr.26th United States Secretary of Health and Human Services since 20251 report
Places
- ChinaChina1 report
- WashingtonWashington, DC, USA1 report
Every outlet we read on this story
11 sources11 outlets1 video
